Skip to main content
MarketStoryBook

ELV in “America Imports the World's Drug Prices”

Elevance Health, Inc.

Bull sideStableExposure: not rated yet

Elevance and its CarelonRx pharmacy-benefit operation stand to benefit from lower branded-drug reimbursement and stronger access to generic and biosimilar substitutes.

ELV impact map — “America Imports the World's Drug Prices”

How this story travels from the headline to ELV’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading ELV impact map…

Price history, marked with story events

Oct 13, 2025 – Oct 13, 2026 · 252 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

America Imports the World's Drug Prices

US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

BULL side — Elevance and its CarelonRx pharmacy-benefit operation stand to benefit from lower branded-drug reimbursement and stronger access to generic and biosimilar substitutes.

Read the full America Imports the World's Drug Prices story

Bull side

1 story
  • ELV in “America Imports the World's Drug Prices”

    StableExposure: not rated yet
    Viewing

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Elevance and its CarelonRx pharmacy-benefit operation stand to benefit from lower branded-drug reimbursement and stronger access to generic and biosimilar substitutes.

Bear side

1 story
  • Managed Care's Margin Machine Breaks

    ELV in “Managed Care's Margin Machine Breaks”

    FadingExposure: not rated yet

    Rising utilization, tougher reimbursement and scrutiny of denials are shifting economics from insurers back to care providers.

    Higher claims trends and government-program rate pressure threaten underwriting margins across Elevance's insurance portfolio.